Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

Launched by INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG) · Jan 17, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on understanding a specific type of cancer called Nodal Marginal Zone Lymphoma (NMZL). Researchers want to improve how this disease is classified and how well they can predict outcomes for patients. They are looking at the genetic and clinical information from patients who have been diagnosed with NMZL to develop a clearer picture of the disease.

To participate in this study, you need to be an adult aged 18 or older who has been diagnosed with NMZL after January 1, 2000. You should also have tumor samples available from when you were first diagnosed, before any treatment. If you decide to join, you'll be part of a study that collects and analyzes information to help improve care for future patients with NMZL. The trial is currently recruiting participants, and it welcomes men and women of all backgrounds.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male or female adults 18 years or older
• • 2. Diagnosis of NMZL on lymph node histology after Jan 1st, 2000
• • 3. Availability of tumor material from lymph node (either frozen or FFPE) collected when the patient was treatment naïve
• • 4. Availability of the baseline and follow-up annotations
• Exclusion Criteria:
• • 1. Nodal spread of a clinically occult extranodal MZL (this must have been ruled out by carefully evaluating the extranodal tissues draining to the involved lymph nodes by imaging or endoscopy)